News & Updates
Filter by Specialty:
Show Multimedia Only
Deucravacitinib delivers superior efficacy, safety in active PsA
10 Jul 2025
byStephen Padilla
Deucravacitinib exhibits superiority over placebo in terms of overall disease activity measures, musculoskeletal and dermatologic manifestations, and quality of life in adults with active psoriatic arthritis (PsA) who are naïve to biologic disease-modifying antirheumatic drugs (DMARDs), according to the results of the POETYK PsA-1 study.
Deucravacitinib delivers superior efficacy, safety in active PsA
10 Jul 2025
Delgocitinib cream safe, effective for long-term use in eczema
07 Jul 2025
byStephen Padilla
Long-term treatment with delgocitinib is well-tolerated and raises no major safety concerns among patients with chronic hand eczema (CHE), results of the DELTA 3 trial have shown. Its use also maintains disease control for up to 52 weeks.
